Background Forkhead box P3 (FOXP3)? regulatory T cells (Tregs) are critical for controlling inflammation in the gastrointestinal tract. There is a paradoxical increase of mucosal FOXP3? T cells in patients with inflammatory bowel disease (IBD). These FOXP3? cells were recently shown to include interleukin (IL)-17A-producing cells in Crohn's disease, resembling Th17 cells implicated in autoimmune diseases. FOXP3 inhibits IL-17A production, but a naturally occurring splice variant of FOXP3 lacking exon 2 (Dexon2) cannot.
Introduction
FOXP3 is a nuclear transcription factor which plays a central role in the differentiation of CD4? T cells into CD25? regulatory T cells (Tregs), to which its expression is largely restricted [1] . Tregs play an essential role in regulating inflammation in the gastrointestinal tract, as humans born with mutations in FOXP3 and mice engineered to lack Tregs both develop severe intestinal inflammation [2] [3] [4] [5] . However, humans with the inflammatory bowel diseases (IBD) Crohn's disease (CD) and ulcerative colitis (UC) do not lack mucosal FOXP3? cells, but rather have a large number of them in the lamina propria and mesenteric lymph nodes, particularly in areas of active inflammation [6] [7] [8] [9] .
In healthy humans (but not mice), roughly half of all FOXP3 is expressed as an alternatively spliced isoform lacking exon 2 (Dexon2) [10, 11] . It is not known whether the two isoforms are coexpressed or expressed in different cells. When transfected into T cells, both full-length and Dexon2 versions of FOXP3 cause the cells to acquire Treg markers and lose their cytokine-secreting capacity [10] . However, there are mutations within exon 2 of FOXP3 that are associated with immune-mediated, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in humans [12, 13] . This suggests that the exon 2 sequence found exclusively within full-length FOXP3 plays a unique and critical role in the maintenance of immune homeostasis in the gut and elsewhere.
Th17 cells are IL-17A-secreting CD4? T cells that have been shown to play a pathogenic role in several models of autoimmunity [14] . Th17s are enriched in the intestinal mucosa of IBD patients [15] , and may play a role in promoting the neutrophilic inflammation that is typical in active IBD [16] . Furthermore, several lines of evidence have implicated a Th17 survival factor, IL-23 [17] , in the pathogenesis of IBD. Genetic correlations have been identified between IBD and polymorphisms in or near the receptor for IL-23 [18, 19] , as well as shared components of IL-23 and the IL-23 receptor's signal transduction cascade [20] . Additionally, clinical trials of an antibody directed at the shared p40 subunit of IL-12 and IL-23 have shown efficacy in treating Crohn's disease [21] . Thus, Th17 cells are likely central mediators of IBD. Although they seem to have diametrically opposed roles in inflammation, Th17 cells and Tregs can both be generated from naïve T cells activated in the presence of transforming growth factor-beta (TGF-b) [22] , a cytokine common to the bowel microenvironment in IBD [23] . Thus, the balance between whether T cells become pro-inflammatory Th17 cells or anti-inflammatory Tregs may be delicate and critical to maintaining gut immune homeostasis.
A unique subset of IL-17-expressing FOXP3? T cells was recently described in the intestinal mucosa, and found to be more common in Crohn's patients than in controls, particularly in inflamed tissues [24] . These cells resemble both Tregs and Th17 cells in their surface protein expression profile, and they coexpress both FOXP3 and the nuclear transcription factor RORct [24] , which plays a central role in the differentiation of CD4? T cells into Th17 cells [25] . FOXP3 can prevent RORct from promoting IL-17A expression in CD4? T cells by a direct interaction [26] involving a region of FOXP3 encoded by its second exon [27] . Thus, while full-length FOXP3 inhibits RORct from promoting Th17 differentiation, the Dexon2 splice variant lacking this exon does not [27] .
We hypothesized that the paradoxically increased number of FOXP3? T cells in the inflamed mucosa of IBD patients may be preferentially expressing the Dexon2 isoform of FOXP3. This could potentially allow these cells to become pathogenic Th17 cells, or otherwise compromise their immunoregulatory potential. However, through immunohistochemistry and real-time PCR, we found no reduction of full-length FOXP3 expression in IBD, nor any preferential expression of Dexon2 transcripts. Furthermore, through immunofluorescence microscopy, we were unable to identify cells that exclusively expressed Dexon2 FOXP3. In cells isolated from colectomy specimens, we did identify FOXP3? cells capable of expressing IL-17A in vitro, but these cells were seen in patients both with and without IBD, and did not preferentially express Dexon2, although they were unusually capable of producing tumor necrosis factor-a (TNF-a). Thus, neither the paradoxically plentiful FOXP3? cells nor the FOXP3? IL-17-expressing cells in the inflamed intestines of IBD patients express exclusively the Dexon2 form of FOXP3.
Methods

Human Subjects
All experiments were performed according to protocols approved by the Institutional Review Board (IRB) at Virginia Mason Medical Center/Benaroya Research Institute. For real-time quantitative polymerase chain reaction (qPCR), immunofluorescence, and flow cytometry Fig. 1 FOXP3? cells are plentiful in IBD. a mRNA was harvested from intestinal mucosa snap-frozen from surgically resected specimens, and evaluated by qPCR for the quantity of FOXP3 transcripts relative to CD4 (right) or GAPDH (left) transcripts. In the right panel, a p value is shown for a Student's t test comparing pooled data points under the two brackets shown. b Serial sections of FFPE colonoscopic biopsies were stained by IHC with antibodies to FOXP3 or CD4 and digitally photographed, and the total numbers of FOXP3? or CD4? cells were quantified by ImageJ, and used to estimate the percent of total CD4? cells that were FOXP3? Tregs. p values are shown for Student's t tests comparing non-IBD specimens with either Crohn's or UC specimens. c H&E-stained serial sections of the samples in (b) from IBD patients were graded for neutrophilic inflammation by a single, blinded GI pathologist, and the Treg frequency in (b) was replotted relative to Crohn's (left) or UC (right) inflammatory grade. d Data in (b) were replotted relative to whether a patient was using a particular medication at time of biopsy (note that some patients were using more than one agent, and so may be represented in multiple columns). For all IHC plots, each dot represents a unique colonoscopy experiments, specimens were obtained from sequential consenting patients undergoing bowel resection for Crohn's disease (n = 10), UC (n = 7) or a non-IBD indication [n = 8, consisting of one case each of hereditary nonpolyposis colorectal cancer (HNPCC), diverticulosis, colon cancer, colonic inertia, and rectal prolapse, and three cases of familial adenomatous polyposis (FAP)] by a single colorectal surgeon (R.C.T.). Non-IBD subject tissue was obtained from healthy, nonneoplastic portions of bowel. IBD subject tissue was from inflamed segments of bowel. For immunohistochemistry (IHC) analyses, billing records were reviewed to identify patients with Crohn's disease (ICD9 555.#), ulcerative colitis (ICD9 556.#) or neither of the above who underwent colonoscopy with biopsy (CPT code 45380). Electronic medical records of patients thus identified were reviewed to confirm diagnosis accuracy and abstract basic demographic information as well as clinical data, including disease characteristics, duration, and treatment. Results were crossed with pathology records to select and retrieve archived colonoscopic biopsies for analysis from 31 patients with Crohn's, 41 with UC, and 14 without IBD (1 with Clostridium difficile colitis, 2 with collagenous colitis, 2 with chronic diverticulitis, 1 with rectal prolapse, and 7 with no identifiable pathology). Sections from historical archived tissue blocks were deidentified for research to be compliant with privacy laws.
Real-Time PCR
Samples of human intestine were obtained fresh from the operating room, immediately snap-frozen in liquid nitrogen, and later thawed, homogenized with an RNEasy kit (Quiagen), and converted to complementary DNA (cDNA). cDNA was probed with commercial primer sets specific to CD4, glyceraldehyde 3-phosphate dehydrogenase (GAP-DH), or FOXP3 using TaqMan (Applied Biosystems) and a 7900HT real-time PCR machine (ABI). FOXP3 probes were selected to span C-terminal sequence (exons [11] [12] , found in all FOXP3 transcripts, or could discriminate between full-length and Dexon2 transcripts by spanning either exon 2 or a junction between exons 1 and 3, respectively.
Histology
Sections of archived, formalin-fixed, paraffin-embedded (FFPE) intestinal tissue were stained with hematoxylin and eosin using an Autostainer XL (Leica Microsystems). These slides were then evaluated by a single blinded pathologist (H.H.) to grade inflammation based upon neutrophilic infiltrate. Biopsies without neutrophilic inflammation were scored as 0. Biopsies showing neutrophilic inflammation (infiltration of surface or crypt epithelium with associated epithelial injury) but without crypt abscesses were scored as 1?. Biopsies with neutrophilic inflammation and crypt abscess formation were scored as 2?. Biopsies with neutrophilic inflammation with severe epithelial injury resulting in mucosal ulceration were scored as 3?.
For IHC, serial sections of formalin-fixed, paraffinembedded intestinal mucosa were deparaffinized, antigenretrieved, and stained on a BOND-MAX immunostainer (Leica Microsystems), using the manufacturer's proprietary reagents. Primary antibodies used for IHC included a murine IgG to the c-terminus of FOXP3, which recognizes both full-length and Dexon2 versions of FOXP3 (clone 236A/E7; eBioscience), a murine IgG specific to sequence corresponding to exon 2 of FOXP3, which therefore cannot recognize the Dexon2 variant (clone 150D; eBioscience), or murine anti-CD4 (clone 4D11; Vector Labs). Sections were photographed in their entirety at low power, and digitally analyzed with ImageJ software (NIH), using a color deconvolution plugin to objectively count individual cells (in the case of FOXP3) or pixels (in the case of CD4, due to cytoplasmic staining and confluency) staining brown [diaminobenzidine (DAB)?] for a given marker. The average number of pixels per CD4? cell was then determined in areas where CD4? cells were not confluent, and then the total number of CD4? pixels per slide was divided by the average number of pixels per CD4? cell to estimate the number of CD4? cells per slide. The number of FOXP3? cells was then divided by the number of CD4? cells to estimate the relative fraction of intramucosal CD4? T cells expressing FOXP3.
Flow Cytometry
Fresh human intestine from the operating room was sharp dissected to isolate mucosa and remove as much muscle and connective tissue as possible. Then tissue was washed and incubated three times with dithiothreitol (DTT) and ethylenediamine tetraacetic acid (EDTA) in calcium and magnesium-free phosphate-buffered saline (PBS) at 37°C to remove epithelium and mucous. The remaining lamina propria was then washed three times with Roswell Park Memorial Institute (RPMI) medium, chopped, and incubated for 90 min at 37°C with RPMI containing collagenase and DNAse. Liberated cells were then washed with PBS and incubated overnight in RPMI containing 10 % Fig. 2 Cells expressing full-length FOXP3 are plentiful in IBD. a mRNA was harvested from intestinal mucosa snap-frozen from surgically resected intestine specimens, and evaluated by qPCR using primers to FOXP3 transcripts that either overlay an exon 1-exon 3 splice junction (and therefore will only amplify Dexon2 transcripts) (green arrows), bind within exon 2 (and thus will only amplify fulllength FOXP3 transcripts) (blue arrows), or recognize sequence corresponding to C-terminal sequence (and so will amplify both Dexon2 and full-length FOXP3 transcripts) (red arrows 
Results
FOXP3? Cells Are Plentiful in IBD
Using primers recognizing the C-terminal transcript of FOXP3, we performed real-time qPCR for FOXP3 on messenger RNA (mRNA) isolated from frozen intestine surgically resected from patients with UC, CD, or no IBD. In addition to the housekeeping gene GAPDH, expression of CD4 was likewise quantified by qPCR, as CD4 was used to standardize FOXP3 expression to total number of CD4 T cells instead of total cellularity in each specimen. FOXP3 expression was no lower in IBD specimens than controls, and relative to CD4, there was a paradoxical increase in the frequency of FOXP3 transcripts in tissue from Crohn's patients or the inflamed portion of UC specimens relative to uninflamed colon from UC patients or controls (Fig. 1a) . We also performed immunohistochemistry (IHC) for FOXP3 and CD4 on serial sections of intestinal biopsies obtained colonoscopically from patients with versus without UC or CD (Fig. 2b , upper panels, shows representative FOXP3 IHC). FOXP3? cells were electronically counted, relative to the density of CD4? T cells in the sections, and were at least as large a fraction of total CD4? T cells in IBD patients as in controls (Fig. 1b) , as has been described previously [6] [7] [8] [9] . When the degree of neutrophilic inflammation present in these sections was graded by a blinded pathologist, and treated as a continuous variable for linear regression analysis, it was found to correlate with FOXP3? T cell frequency in specimens from patients with Crohn's disease (Fig. 1c, left panel, Pearson's r = 0.5135, p = 0.0044) but not UC (Fig. 1c, right panel, r = -0.01984, p = 0.8983). Thus, not only were FOXP3? T cells plentiful in the mucosa of Crohn's patients, but they were paradoxically more common in more severely inflamed tissue. No correlations were found between FOXP3? T cell frequency and patient age, gender, disease duration, biopsy location, Crohn's complications (strictures, abscesses or fistulas) (data not shown), or treatment (Fig. 1d) by linear regression analyses, analysis of variance (ANOVA), or Student's t test, as appropriate.
Cells Expressing Full-Length FOXP3 Are Plentiful in IBD
To determine the fraction of FOXP3 transcripts encoding full-length versus Dexon2 FOXP3, we performed real-time PCR on the mRNA from Fig. 1a , using primers that spanned either exon 2 (present only in full-length FOXP3 transcripts) or the junction between exons 1 and 3 (present only in Dexon2 transcripts). When divided by the frequency of total FOXP3 transcripts (from which the data in Fig. 1a were generated), transcripts containing exon 2 (and thus full-length FOXP3) were no less common, and those containing the Dexon2 splice junction were no more common, in IBD than in controls (Fig. 2a) . In fact, there was a nonsignificant trend towards fewer Dexon2 transcripts in IBD.
To confirm this finding at the protein level, and demonstrate the histological distribution of cells expressing full-length FOXP3, we also performed IHC with an antibody (clone 150D) recognizing only the exon 2 domain (and thus only fulllength FOXP3, not Dexon2). Using serial sections from the same biopsies analyzed in Fig. 1b-d , we found copious fulllength-FOXP3? cells present in the lamina propria and Fig. 3 FOXP3? cells in IBD are exon 2? . a A frozen section from the surgically resected mesenteric lymph node (MLN) of a patient with UC was simultaneously stained with exon 2-specific mouse anti-FOXP3 (clone 150D, green) and nonspecific rat anti-FOXP3 (clone PCH101, red), revealing no FOXP3? cells recognizable by the latter which were not also expressing exon 2 (merged) lymphoid follicles of both IBD patients and controls, with a tissue distribution similar to that of total FOXP3? cells in Fig. 1 (Fig. 2b) . Again, when divided by the CD4? T cell density in sections, there were no fewer full-length-FOXP3? cells in IBD patients than in controls (Fig. 2c, left panel) . When the ratio of full-length to total FOXP3? cells was calculated for each specimen, there was no qualitative difference between IBD patients and controls (Fig. 2c, right panel) .
FOXP3? Cells in IBD Are Exon 2?
The data in Figs. 1 and 2 could not exclude the possibility that a small number of FOXP3? cells in IBD patients expressed exclusively the Dexon2 form of FOXP3. Therefore, we stained frozen sections from the surgically resected tissue of IBD patients with both nonspecific and exon 2 (e.g., full length)-specific antibodies to FOXP3, plus anti-CD3, by three-color immunofluorescence. Cells recognized by both anti-FOXP3 antibodies were readily identified (Fig. 3a) , but not a single cell was found that would be recognized by C-terminus-specific anti-FOXP3 (clone PCH101) without also being labeled by exon 2-specific anti-FOXP3 (clone 150D). Thus, no cells expressing exclusively Dexon2 were identified. For flow cytometry, we similarly stained collagenaseliberated cells from the surgically resected colons of patients with or without IBD, using both nonspecific and exon 2-specific anti-FOXP3 antibodies. We again found few cells that were positive for nonspecific anti-FOXP3 but negative for exon 2-specific anti-FOXP3 (Fig. 3b) , as there was a direct correlation in fluorescence between the two antibodies. (Fig. 3c) , with a greater percentage of FOXP3? than FOXP3-T cells able to make IL-17 in specimens from IBD patients, although this difference was not statistically significant in patients without IBD (Fig. 3e, left panel) . When gated on FOXP3? cells, a fraction of those specifically expressing exon 2? full-length FOXP3 (which were the majority of FOXP3? cells) were likewise able to produce IL-17 ( Fig. 3d) , with more exon 2? than exon 2-T cells able to make IL-17 ( (Fig. 3e,  right panel) . Again, these differences were not significant in specimens from patients without IBD. Discussion FOXP3? Tregs are critical mediators of intestinal immune homeostasis [2] [3] [4] [5] , and yet are paradoxically present in increased frequency in the bowels of IBD patients [6] [7] [8] [9] . We show here that this paradox is not explained by preferential expression of FOXP3 in its shortened Dexon2 isoform in IBD. Furthermore, we find no evidence that T cells exclusively expressing Dexon2 predominate among a subset of FOXP3? T cells capable of producing IL-17 in vitro.
The latter cells have been described previously in the blood of normal donors [28, 29] and in the intestinal mucosa of patients with Crohn's disease, where expression of the Th17 differentiation transcription factor RORct correlated with IL-17 production [24] . We confirmed that a higher fraction of FOXP3? than FOXP3-T cells in the intestinal mucosa of IBD patients could make IL-17, although the lack of a similar correlation in patients without IBD was due more to a higher fraction of IL-17? FOXP3-T cells and greater overall heterogeneity in these patients than a lower frequency of IL-17? FOXP3? T cells, as has been described [24] . We find that, in normal peripheral blood mononuclear cells (PBMC), as in the intestine, these IL-17-producing FOXP3? cells contain exon 2 (data not shown). The inability of endogenously expressed full-length FOXP3 to prevent IL-17 production by CD4? T cells appears to contradict a model in which cotransfection of full-length FOXP3, but not Dexon2 FOXP3, with RORct prevented the latter from causing the T cells to secrete IL-17 [27] . It is possible that, in FOXP3? PBMC and intestinal T cells, IL-17 secretion is mediated by an RORct-independent mechanism, resistant to inhibition by FOXP3. Alternatively, endogenous FOXP3, in contrast to transfected FOXP3, may not be expressed at high enough levels to prevent RORct from causing IL-17 secretion. Finally, it is possible that the in vitro stimulation with PMA and ionomycin that we used to detect cytokine production by flow cytometry was too potent for FOXP3 to prevent IL-17 secretion.
We found that more IL-17? than IL-17-FOXP3? T cells were able to produce TNF-a, and in IBD patients we noted the former cells to even be more able to make TNF-a than FOXP3-T cells. TNF-a is presumed to be central to the pathogenesis of IBD, as it is a primary target of effective pharmacotherapy for both UC and Crohn's disease. Thus, it is paradoxical for a presumed regulatory population of FOXP3? cells to be a potent source of such a pro-inflammatory cytokine. Future research may elucidate whether such a paradox is a cause or effect of disease pathogenesis.
We confirmed that the number of intramucosal FOXP3? T cells correlates with the degree of tissue inflammation present. Furthermore, ex vivo analyses have not identified any specific defect in the ability of these cells to inhibit the proliferation of other T cells [6] [7] [8] 30] . It is possible that these in vitro assays fail to capture some of the more subtle inhibitory effects through which Tregs function in vivo, and which could be defective in IBD. Alternatively, there may be cells or factors in the intestinal microenvironment which negate the inhibitory effect of Tregs in the mucosa. Clearly there are more pro-inflammatory cells and cytokines in the inflamed mucosa of IBD patients, against which even a robust Treg response may simply be insufficient. However, if there are specific molecular signals that prevent Tregs from controlling inflammation, they would represent attractive targets for therapeutic intervention, as any agent capable of blocking them could unfetter the central role that Tregs normally play in maintaining gut immune homeostasis.
